12
Participants
Start Date
September 30, 2000
Primary Completion Date
January 31, 2006
Study Completion Date
March 31, 2006
Thalidomide, alpha interferon
If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.
Thalidomide, interferon, Octreotide
If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
University of New Mexico, Albuquerque
New Mexico Cancer Care Associates, Santa Fe
University of New Mexico
OTHER